Introduction
Since the mid 1980s adenoviruses (Ads) have been given considerable attention as potentially clinically viable gene transfer agents. [1] [2] [3] Likewise, the use and improved efficacy of Ads as a vaccine platform has also been a recent subject of intense investigation. [4] [5] [6] However, major limitations to the most used serotype of Ad, human Ad5 (HAd5)-based vectors, also exist. For example, subsequent to intravenous (i.v.) injection, HAd5 generally targets the liver, which ubiquitously expresses the major HAd5 receptor coxsackievirus-Ad receptor (CAR). 7, 8 This limits the use of HAd5 as a tumor-directed gene transfer vector, in which targeting only affected cancer tissue (and minimizing liver tropism and/or associated hepatotoxicities) would be ideal. It is also known that i.v. injection of high-titer HAd5-based vectors can cause several innate immune responses and hepatotoxicities, some associated with activation of complement and Toll-like receptor (TLR) pathways. [9] [10] [11] These responses can include induction of thrombocytopenia, and expression of a spectrum of cytokines and chemokines including interleukin (IL)-1a, IL-6, IL-12, keratinocyte chemoattractant (KC), monocyte chemotactic protein-1 (MCP-1), granulocyte-colony stimulating factor (G-CSF), interferon (IFN)-g, macrophage inflammatory protein-1 (MIP-1)b and RANTES (regulated on activation normal T-cell-expressed and -secreted). To avoid hepatotoxicities induced by HAd5, several efforts to alter HAd5 tropism have been described. Although in vitro detargeting and/or retargeting strategies have shown great promise (for example by ablating the CAR-binding domains of the fiber knob domain), studies of these same vectors have proven that these modifications many times do not show similar efficacies in vivo. [12] [13] [14] More importantly, HAd5 is a common pathogen, with more than 50% of US adults having been previously exposed, and more than 80% in some parts of Africa. Therefore, pre-existing anti-HAd5 immunity may further limit the effectiveness of HAd5-based vectors, for example as an HIV vaccine. In an attempt to address these concerns, the use of alternative HAd serotypes as well as non-HAds, has been proposed as a means to overcome limitations based on use of the HAd5 serotype.
There are currently over 50 HAd serotypes that make up the six human subspecies, referred to as subspecies A-F. Ad serotypes from all human subgenera use CAR as a receptor with the exception of group B Ads and some group D Ads (for example, HAd37) that use a variety of receptors including CD46, sialic acid and the unknown receptor 'X'. [15] [16] [17] Multiple Ad serotypes are currently under investigation for their potential ability to uniquely target various tissues and/or evade HAd5-specific innate and adaptive immune responses. 18, 19 To date, various members of groups A-F have been vectorized and evaluated in vitro and/or in vivo. These alternative serotype vectors have been demonstrated to show altered cell-type tropisms, retain their ability to avoid neutralizing antibodies to other Ad serotypes and can also stimulate antigen-specific CD8+ T-cell responses to transgenes they encode. 20, 21 However, little is known about the acute toxicities and biodistribution profiles that these alternative Ad serotypes might engender, relative to the HAd5 platform. Furthermore, there are simian, ovine, bovine, porcine, avian and canine Ads that are also potentially amenable for use as gene transfer or vaccine vectors. [22] [23] [24] In this study, we characterize several innate immune responses generated by wild-type HAds of each subgenera A-D and F, as well as a simian-derived Ad, SAd23 (previously designated Pan 6, which is closely related to the subgenera E). We demonstrate a unique set of serotype-specific biodistribution patterns, host cell gene inductions, acute toxicities and plasma cytokine profiles after a vigorous in vivo assessment. Furthermore, this study highlights the important role the complement system has in the induction of portions of these serotypespecific toxicities, dependencies originally noted after use of HAd5 vectors. 10 In summary, this study reveals that use of alternative Ad serotypes to address one set of concerns may also precipitate another set of unforeseen problems and/or limitations inherent to each serotype's biology. This knowledge will inform the decision to proceed with a respective virus serotype for use as a gene-transfer vector in diverse gene therapy or vaccine applications
Results

Alternative serotype Ads exhibit significantly different biodistribution patterns in vivo
One of the major problems facing Ad-mediated gene transfer in humans is the prevalence of pre-existing immunity to HAd5 serotypes. 25 In most cases, alternative serotype Ads are not cross-neutralized by antibodies directed against another serotype. 26, 27 Furthermore, the incidence rate of seroconversion to many alternative serotype HAds in many cases are significantly lower than the seroconversion rates noted for HAd5. 28 These facts have justified multiple investigations into the use of alternative serotype Ads for potential use in numerous human gene transfer applications. 29 However, it is also likely that using alternative serotype Ads may also generate unanticipated biological consequences. For example, our laboratory has previously vectorized a HAd4-based gene transfer platform and noted that the resulting vector had a significantly altered biology and innate immune response profile relative to a HAd5-based vector, as assessed by numerous in vitro and in vivo studies. 30 In this study, we wanted to expand upon those observations relative to several alternative human-or simian-derived Ads spanning the six HAd subgenera. We, therefore, selected and characterized a member of each subgenera: A (HAd31); B (HAd3); C (HAd5); D (HAd37) and F (HAd41), as well as simian derived Ad 23 (SAd23) also known as Pan 6.
To accurately compare each virus, we quantified viral particle titers using the previously described OD 260/280 method as well as hexon protein quantification (Supplementary Figure 1 ). 31 We noted that viral particle quantification using the SDS-disruption method was slightly different between HAd5 and the alternative serotype Ads tested in this study. For example, when 10 10 particles (viral particle numbers were solely based on OD 260/280 ratio), of a respective wild-type virus were assayed for levels of hexon protein by protein visualization and quantification, levels of Ad hexon were three-to fivefold higher in HAd5 preparations relative to the other serotypes tested. For this reason, we injected two different doses of HAd5, each corresponding to 7.5 Â 10 10 vp per mouse depending on quantification method. These doses are designated HAd5(D); dose based on DNA quantifications or HAd5(P); dose based on hexon protein quantification.
We first evaluated the biodistribution of each wildtype Ad serotype after systemic (i.v.) administration of equivalent particle numbers of each virus into fully immunocompetent, Ad naïve, C57BL/6 mice. By using quantitative PCR to detect the specific serotype genomes, we quantified the amount of the respective Ad genomes in liver, lung, kidney, spleen and heart tissues at 6 and 24 h.p.i. (Figure 1 ). At early time points after virus administration, all serotypes tested were found to have a high concentration of their genomes localized to the liver, confirming that hepatic localization appears to be serotype independent. Interestingly, at both doses of HAd5, we observed a greater than 60-fold increase in HAd5 genomes from 6 to 24 h.p.i. in the liver, a result in accord with previous studies directly or indirectly noting that HAd5 can indeed replicate its DNA to a limited degree upon infection of the murine liver. [32] [33] [34] [35] In contrast, although each of the other Ad serotype genomes were detected in the murine liver at 6 h.p.i., none showed evidence of significant genomic increases (replication) by 24 h.p.i. In fact, there was a significant decrease in the liver content of HAd3, HAd37 and HAd41 genomes by 24 h.p.i. (Po0.01) . Of all the serotypes tested, HAd31 genome content was at the lowest in liver at 6 h.p.i., a level essentially equivalent to HAd31 genome levels noted at 24 h.p.i. Although HAd5 genomes were primarily detected in the liver, they were also detected, albeit at significantly lower levels, in the lung, kidney, spleen and heart at both 6 and 24 h.p.i. (Po0.001). Interestingly, mice identically injected with HAd3 were found to contain significantly higher levels of the HAd3 genome in the lung at 6 and 24 h.p.i., relative to the number of HAd3 genomes quantified in the livers of the same animals (Po0.001). In fact, no other Ad serotype paralleled this level of lung distribution, suggesting that unique characteristics of the HAd3 capsid allow for an enhanced propensity of the virus to localize to both the liver and the lung.
Other interesting findings included the observation that at 6 h.p.i., HAd37 genomes could be detected at high levels in both the liver and spleen, with quantities 30 This acute response primarily manifested as behavior characterized by a delayed return to sternal recumbency, decreased activity once recumbent and tachypnea. These behavioral phenotypes were not observed in mock-injected mice, or in mice injected with the remaining four serotypes, suggesting that these observations may reflect different innate immune responses that are dependent on Ad serotype. We, therefore, evaluated these observations in a more quantitative fashion.
Our recent publications describe the specific transcriptome profile of Ad-infected mouse embryonic fibroblasts in vitro, and the general transcriptome responses in the livers of Ad-injected C57BL/6 mice in vivo. 9, 10, 36 The results of these array-based analyses indicated a global induction of host immune response genes, inclusive of several immune response gene networks, such as TLR pathways among others. From these analyses, it became clear that many known innate immunity genes, such as NOD-like receptors and TLRs were induced following Ad injection, and that TLR adaptor proteins, such as MyD88 and TRIF were required in Ad-specific innate immune responses. 9, 36 Furthermore, Ad-induced type I IFNs as well as IL-6 and IL-12 have been found to be partially dependent on -and HAd41-injected animals, n ¼ 3 for all tissues at both 6 and 24 h.p.i. n ¼ 4 at both time points for HAd5(P)-injected animals. For HAd3-injected animals, n ¼ 3 for all tissues at 6 h.p.i., n ¼ 7 for liver and spleen at 24 h.p.i. and n ¼ 4 for the remaining tissues at 24 h.p.i. For SAd23-injected animals, n ¼ 3 at 6 h.p.i. and n ¼ 3 at 24 h.p.i. for all tissues. For HAd31-and HAd37-injected animals, n ¼ 3 for all tissues tested at 6 h.p.i., as well as heart, kidney and lung tissue at 24 h.p.i., and n ¼ 6 for livers and spleens tested at 24 h.p.i. * indicates a statistically significant difference between the serotype being tested compared with HAd5 at the indicated time point (Po0.05). # indicates a statistically significant difference between the indicated serotype at 6 versus 24 h.p.i. (Po0.05 or Po0.01, respectively). Bars represent the mean and error bars represent the standard deviation. For HAd5, bars represent one of replicate experiments (n ¼ 3 at each time point for both). Ad, adenovirus.
Innate immune responses to alternative Ad serotypes DM Appledorn et al TLR9. [37] [38] [39] In light of these data, we analyzed the expression of a selected subset of these Ad-induced genes to determine whether alternative Ad serotypes influenced the expression of these genes in a manner similar to that previously noted for HAd5 ( Our previous studies showed that maximal changes in liver transcriptome responses occur 6 h after Ad injection. 9 The expression of most of these genes (except for TLR9, NAÀN=1 for data generated from this primer pair. ANOVA followed by a Dunnet's post hoc test was completed to determine a statistical difference versus mock injected animals. These differences are indicated in the table with light gray boxes (Po0.05). ANOVA followed by Tukey's post hoc test was completed to determine significantly different increases versus HAd5(D). These differences are indicated in the table with dark gray boxes and boldface font (Po0.05).
Innate immune responses to alternative Ad serotypes DM Appledorn et al which was induced only by HAd41), were significantly induced by all serotypes in the livers of all animals tested ( Table 1 ). The genes induced by HAd5 at both particle dosages included IRF-7, MyD88, NOD1, TBK1, TLR2 and TLR6. Interestingly, the extent to which these genes were induced by HAd5(P) was not significantly different than that noted after treatment with the HAd5(D) dose, indicating a threshold had been reached. In more general terms, the serotype that induced the most robust expression profile was HAd41. Notably, all alternative serotypes induced significantly higher levels (on the order of 3-4 fold) of TLR2 than did HAd5. Furthermore, HAd3 and SAd23 induced significantly higher levels of the SOCS genes than did HAd5. HAd5, HAd31 and HAd37 also induced expression of many genes tested in our array; however, their respective gene induction capabilities were relatively lower than that noted after administration of HAd3, SAd23 and HAd41. As high levels of HAd3 genomes were detected in the lung, we next evaluated the induction of the same set of genes in lung tissue (Table 1 ). In liver, we observed significantly less gene induction by HAd31 and HAd37 as compared with HAd3, SAd23, and HAd41, whereas we found that the overall gene induction elicited by HAd31 and HAd37 viruses in the lung were now significantly greater than that induced by both SAd23 and HAd41. In fact, the level of increased gene expression in the lung following HAd31 and HAd37 injection was not statistically different than that induced by the 'lung tropic' HAd3. Levels of IRF-7 and NOD1 induced by HAd3, HAd31 and HAd37 were statistically higher in the lung when compared to fold increases of these same genes in the livers of the same animals. Lung and liver expression levels of IRF-8, NOD2, SOCS2, TBK1, MyD88 or TLR9 were not statistically different. In contrast, increases in the transcription of genes encoding SOCS1 and TLRs 2, 3 and 6 by all serotypes were much greater in the liver than they were in the lung. We also observed that induction of IRF7 was significantly higher in the lung when compared with liver from mice injected with five of the six serotypes; the exception being SAd23, where a similar trend was no less observed, but did not reach statistical significance.
As the majority of the cellular population of the spleen consists of professional immune cells, we next evaluated the transcriptional induction of the same set of genes in splenic tissue ( Table 1) . As in the liver, we saw a general induction of gene expression as a result of Ad serotype injections. However, in only rare instances, for example, SOCS2,-3 in the spleen of HAd5-injected mice and SOCS3 in the spleen of HAd37injected mice, the fold induction was significantly higher than the induction of the same gene in the liver collected from the same mouse. Of note, in mock-injected C57BL/6 animals, expression of every gene tested in this analysis was significantly greater in both the spleen and the lung relative to their absolute levels quantified in the liver, with the highest levels of IRF7,-8, SOCS1, TBK1, TLR6 and TLR9 transcription found in the spleen (Supplementary Table 2 ). Finally, in most cases, all TLR genes were induced to significantly higher levels in the livers of mice injected with any of the Ad serotypes tested relative to the transcriptional inductions noted in either the lung or the spleens of the same animals. These data clearly illustrate the diverse serotype and tissue-specific immune gene responses that these viruses elicit following i.v. injection.
Induction of plasma cytokines and chemokines by Ads is serotype dependent
Exposure to HAds is known to induce a complex series of chemokines and cytokines both in vitro and in vivo. 9, 11, 36 This innate inflammatory response 'profile' has implications in the use of Ad as both a vaccine as well as a vector for gene therapy applications. For this reason, we characterized the acute inflammatory response induced by each of the various Ad serotypes and compared those responses to those typically induced by HAd5 (Figure 2 ). Utilizing a multiplex bead-based system for the simultaneous detection of 23 murine cytokines and chemokines, we analyzed plasma samples at 1, 6 and 24 h.p.i. from mice identically injected with each of the various Ad serotypes.
We have reported previously that HAd5 causes an acute rise in KC. 9, 10, 36 In accord with those observations, we again noted a significant increase in plasma levels of KC 1 h.p.i. in HAd5-injected mice as well as HAd3-injected mice (Po0.05), but we did not observe plasma KC inductions by the remaining Ad serotypes tested ( Figure 2 ). By 6 h.p.i., plasma KC levels had returned to baseline in the HAd5-and HAd3-injected mice.
At 6 h.p.i., HAd5-injected mice also had significant increases in plasma levels of IL-6, IL-12, MIP-1b and the anti-inflammatory cytokine IL-10 (Po0.05). Several of the alternative serotype Ads induced variable cytokine and chemokine levels at this critical time point in murine plasma. For example, animals injected with HAd3 and SAd23 had significantly higher plasma levels of IL-6 and MIP-1b, while HAd41-injected mice exhibited higher plasma IL-12 levels than mice injected with HAd5 (Po0.05). Furthermore, at these dosages, several cytokines or chemokines were not significantly elevated in HAd5-injected mice, but were significantly increased in mice injected with one or more of the alternative serotype Ads. For example, plasma IL-1a and G-CSF levels were significantly elevated in HAd3-and SAd23-injected mice, IFN-g levels were increased in HAd3-, HAd37-and HAd41-injected mice, RANTES levels were increased in HAd3, HAd31, HAd37 and HAd41, and MCP-1 levels were elevated in mice injected with all serotypes except HAd5 (Po0.05).
The kinetics of plasma cytokine and chemokine elevations were also altered in mice treated with alternative serotype Ads. By 24 h.p.i., previously elevated plasma cytokine or chemokine levels noted in HAd5-injected mice had returned to baseline levels. In contrast, RANTES levels were still significantly elevated at 24 h.p.i. after injection with any of the alternative serotype Ads (Po0.05). IL-6 and IL-12 were also significantly elevated at 24 h.p.i. after injection with HAd31, HAd37 or HAd41 (Po0.05). Intriguingly, plasma IL-10 levels were also significantly elevated at 24 h.p.i. in all Ad-injected mice, again except for those injected with HAd5 (Po0.05).
Ad-induced thrombocytopenia and Kupffer cell depletion is serotype dependent
It is well known that exposure to high doses of wild-type HAd5 and HAd5-based vectors can induce Innate immune responses to alternative Ad serotypes DM Appledorn et al thrombocytopenia within hours of i.v. injection. 40 The mechanism by which Ad induces platelet destruction is a dose-dependent, consumptive phenomenon. [40] [41] [42] [43] At the doses of vector particles used in this study, however, we found that injection of HAd5, HAd31 and HAd41 did not result in significant decreases in blood platelet numbers measured at 24 h.p.i. (Figure 3 ). However, identical particle number injections of HAd3, SAd23 and HAd37 resulted in significant thrombocytopenia at this early time point (Figure 3 ). These data indicate that serotypes representing Ad subgroups B, D and E (the latter represented by SAd23 as well as HAd4) may be more capable of inducing thrombocytopenia than subgroups A, C and F when introduced into animals. 30 Kupffer cells are resident macrophages found within liver sinusoids and represent the first line of defense against viruses entering the liver via the circulation. The activation of Kupffer cells is associated with the release of proinflammatory cytokines and chemokines resulting in chemotaxis of various professional immune cells to sites of inflammation. It is well known that i.v. injection of HAd5-based vectors results in Kupffer cell lysis and destruction within hours of virus administration. 44 To determine whether Ad-induced Kupffer cell toxicities were serotype dependent, we stained cryo-frozen liver sections with the macrophage-specific F4/80 antibody at 24 h.p.i. of each respective serotype ( Figure 4 ). As shown in Figure 4 , we found that injection of each serotype resulted in a significant decrease in the Kupffer cell population, but the extent of this was also found to be serotype dependent. For example, HAd5 (at both doses), HAd3 and SAd23 were the most toxic, resulting in a complete elimination of liver resident Kupffer cells by 24 h.p.i. In contrast, 30-40% of Kupffer cells remained detectable in liver sections from mice injected with HAd31, HAd37 or HAd41 (Po0.01) at this same time point. These data indicate differing interactions of alternative serotype Ads with liver resident Kupffer cells that may dictate the previously altered innate immune responses we have also noted. All serotypes resulted in Figure 2 Alternative adenovirus serotype-specific induction of cytokines and chemokines. The Bio-Rad mouse cytokine 23-plex assay system was used to determine plasma cytokine levels in C57BL/6 mice identically injected with the indicated HAd serotype. Error bars denote standard deviation. At 1 h.p.i., n ¼ 4 for mock-injected animals, n ¼ 4 for HAd5(P)-, n ¼ 3 for HAd5(D)-, n ¼ 3 for SAd23-and n ¼ 4 for HAd3-, HAd31-, HAd37-and HAd41-injected animals. At 6 h.p.i., n ¼ 6 for mock-injected animals, n ¼ 6 for HAd5-, n ¼ 8 for HAd3-, n ¼ 4 for SAd23-and HAd37-, and n ¼ 5 for HAd31-and HAd41-injected mice. At 24 h.p.i., n ¼ 8 for mock-injected mice, n ¼ 6 for HAd5-, HAd3-, HAd37-and HAd41-injected mice, and n ¼ 5 for SAd23-and HAd31-injected animals. * indicates a statistically significant difference between mock-injected animals using ANOVA followed by Dunnet's post hoc test (Po0.05). # designation indicates a statistical difference in cyto/ chemokine levels detected in mice injected with HAd5 versus levels detected in mice injected with the indicated Ad serotype at a given time point using ANOVA followed by Tukey's post-hoc test.; ANOVA, analysis of variance.
Innate immune responses to alternative Ad serotypes DM Appledorn et al modest increases in plasma alanine aminotransferase (ALT) levels at 24 h.p.i., increases that did not vary with serotype (data not shown).
HAd3 and SAd23 activate complement in human serum
Our previous work has highlighted a partial role for complement in Ad-induced liver transcriptome responses, cytokine inductions and thrombocytopenia following i.v. HAd5 injections. 10 We have also shown that HAd5 can directly activate the alternative complement pathway in both mouse and human serum, even in serum lacking anti-HAd5 antibodies. 10, 45, 46 To determine whether the complement system is similarly activated in human serum when exposed to what appeared to be the most inflammatory of the alternative serotype Ads (HAd3 or SAd23), we completed AP50 assays and C4 depletion assays to evaluate activation of the alternative and/or classical complement pathways, respectively, by each of the virus serotypes ( Figure 5 ). In this assay system, a decrease in activity indicates consumption of complement components by the respective Ad. Therefore, a decrease in activity indicates activation of the respective complement pathway after exposure to the serotype indicated. The results of these assays indicated that the alternative pathway is activated by all three Ads tested ( Figure 5 ). Of note, both HAd3 and SAd23 showed evidence of greater alternative complement pathway activation than did HAd5 at equivalent particle numbers. We did not detect a significant difference in alternative pathway activation between HAd3 and SAd23, nor did we detect activation of the classical pathway by any virus tested based on the results of the C4 assay.
HAd3-and SAd23-induced gene expression and plasma cytokine and chemokine levels are partially complement dependent in vivo
We have published that HAd5-based vectors induced transcriptome changes, and the increased plasma levels of KC, IL-6, G-CSF, IL-12 and RANTES are, in part, complement dependent. 10, 46 For this reason, we sought to Figure 3 Ad-induced thrombocytopenia. Blood samples were collected from uninjected (N), mock-injected and Ad-injected C57BL/6 animals at 24 h.p.i., and platelets were enumerated using a hemocytometer. n ¼ 4 for uninjected HAd5(P), and HAd31-injected animals, n ¼ 10 for mock-injected animals, n ¼ 6 for HAd5(D)-, HAd3-, HAd37-, HAd41-injected animals, and n ¼ 5 for animals injected with SAd23. * denotes statistical significant difference compared with mock-injected animals (Po0.05). Ad, adenovirus. Innate immune responses to alternative Ad serotypes DM Appledorn et al evaluate the role that the complement system may have in the heightened transcriptome, cytokine and chemokine responses, thrombocytopenia and liver toxicity we noted after specific injection of either HAd3 or SAd23. To do this, Ad naïve C3-deficient, Factor B-deficient (FB; alternative complement pathway deficient) and C57BL/6 mice were injected with an identical dose of each respective virus. Liver, lung and spleen tissue as well as plasma samples were then analyzed 6 h.p.i. Although deficiency in either C3 or FB did not alleviate the observed acute clinical observations we previously made following injection with either HAd3 or SAd23, we did find that lack of complement activity significantly altered both expression of immune response-related genes as well as plasma levels of various cytokines. We first noted that background expression of genes evaluated in this study did not significantly differ in mock-injected C57BL/6, C3-KO and FB-KO mice in any tissue tested (data not shown). However, significant alterations in the liver gene expression profile were observed in both C3-and FB-deficient mice injected with viruses (Table 2) . SOCS-1 was the most notable gene whose expression was partially dependent on C3 and/or FB in the liver of mice injected with SAd23 (303.0 ± 79.0 in C57BL/6 versus 151.3±48.7 and 167.5±19.0 in C-KO and FB-KO mice, respectively). Although the induction of IRF transcripts was not affected, we observed generally higher transcription levels of NOD2, SOCS-2, SOCS-3, TBK1 and several TLR genes in the livers of both C3-and FB-deficient mice injected with HAd3 compared with their C57BL/6 counterparts. In contrast, in lung tissue collected from mice injected with HAd3, induction of all genes queried on the array, (except TBK1 and TLR9) were found to be dependent on the presence of functional FB. Out of these, only MyD88 and TLR6 were found to be dependent on both C3 and FB. Specifically, the IRFs, NODs, SOCS-1,-2,-3 and TLR2,-3.-6 were all found to be dependent on FB to a greater degree than C3.
There were no dramatic differences in the expression levels of these same genes in the lungs of SAd23-injected wild-type, C3-KO or FB-KO animals, nor the spleens of HAd3-injected wild-type, C3-KO or FB-KO mice. However, increased splenic levels of IRFs, NOD2, SOCS2 and TBK-1 transcripts were found in C3-and/or FB-deficient mice injected with SAd23. These data indicate a specific role for several complement pathways in the induction of various immune response genes by Ads, and highlight the tissue specific roles of both C3 and FB in the transcriptome response to several different Ad serotypes. We also observed serotype-specific, complement-dependent expression of plasma IL-12, MCP-1, MIP-1b, IL-1a and IL-10 6 h following injection of the same serotypes ( Figure 6 ). Specifically, in response to HAd3, plasma levels of IL-12, MCP-1 and MIP-1b were all significantly less in C3-deficient animals compared with their C57BL/ 6 counterparts (Po0.05). Additionally, levels of IL-1a, IL-10, IL-12, MCP-1 and MIP-1b were dependent on FB (Po0.01), indicating the requirement of the alternative complement pathway for these responses. Likewise, increases in plasma levels of IL-1a, IL-10 and MIP-1b following SAd23 injection were found to be partially dependent on both C3 and FB (Po0.05). Notably, levels of IL-6 were also modestly reduced in both C3-and FBdeficient mice following injection with either HAd3 or SAd23 (although this trend did not reach statistically significance). In contrast, the induction of G-CSF was not affected in FB-deficient mice, but was found at significantly higher levels in the plasma of C3-deficient animals injected with SAd23, suggesting a possible role for the classical arm of the complement system in this SAd23-induced response.
We have also detected a role for complement in thrombocytopenia following high-titer HAd5 vector administrations, thus signifying the requirement of C3 for Ad-induced platelet consumption. 10, 46 Therefore, we hypothesized a potential role for complement in the thrombocytopenia induced by systemic injection of HAd3 and SAd23 (Figure 7a ). However, we continued to observe a significant decrease in platelets in C3-KO and FB-KO mice injected with either Ad tested at 24 h.p.i. (Po0.05), suggesting that at these particle doses, these viruses induce thrombocytopenia in a complementindependent manner.
We also evaluated virus biodistribution patterns and plasma ALT levels in each knockout strain injected with either HAd3 or SAd23 (Figures 7b and c) . In accord with the observations in C57BL/6 mice, we found similar patterns of virus biodistribution in the liver and lung of HAd3-injected mice as well as the liver and spleen of SAd23-injected animals (Figure 7b ). In contrast, plasma ALT levels were significantly reduced in FB-deficient mice compared with either C57BL/6 or C3-deficient mice injected with SAd23 (Po0.05) (Figure 7c) . A similar trend was observed in mice injected with HAd3; however, statistical significance was not achieved. These data indicate that while the biodistribution of HAd3 or SAd23 and their capability to induce thrombocytopenia are not complement dependent at these viral doses, the alternative complement pathway component FB may have a specific role in HAd3-or SAd23-specific Ad-induced liver toxicities noted shortly after viral inoculation. HAd24, HAd26 and HAd36 50 and the lone member of group E, HAd4, which was recently vectorized and characterized in our lab. 30 In addition, first generation ) have been constructed.
The Ad capsid has a profound effect on cell tropism observed in vitro, and this can translate into unexpected biodistribution profiles in vivo. This may be just as much a consequence of differing receptor usage for example CAR, 8 CD46, 16 MHC class I, 55 heparin sulfate proteoglycan-binding, 56 and sialic acid-containing receptors, 15 as well as differing interactions with blood factors such as opsonins, or other pathogen sensors of innate immunity, for example complement. 41, 57 For example, CAR-ablated Ads seem to retain their liver targeting capabilities in vivo. 58 Our findings that group B member HAd3 was found at high levels in the lung is consistent with previous findings noted with the CD46 utilizing group B HAd11. 59 However, this contrasts with a recently published study that evaluated biodistribution of HAd3 in CD46 transgenic mice. 60 As our studies were completed in mice that were not transgenic for the CD46 receptor, our results suggest a CD46-independent ability for group B Ads to concentrate in the murine lung. As suggested by a recent study, these results may indicate utilization of the unknown group B receptor 'X', used specifically by HAd3, HAd7 and HAd14 in this tropic phenomenon. 17 We also found high levels of the group D representative HAd37 in the spleen as well as the liver, levels similar to those quantified for HAd5. Like group B Ads, HAd37 also uses CD46 as a receptor, but i.v. injection results in a biodistribution pattern distinctly different than HAd3, further supporting the use of an alternative receptor such as sialic acid and/or alternative interactions with pathogen opsonizing blood or cellular proteins. 15 Because the spleen houses a variety of professional immune response cell types, high levels of HAd37 accumulation in the spleen may help to explain why HAd26, also a rare group D Ad serotype, efficiently stimulates a high level, antigen-specific CD8+ T-cell response even in the presence of HAd5 antibodies. 20 Although both SAd23 and HAd31 were detected at both 6 and 24 h.p.i. in the CAR expressing murine liver and the spleen, the relative low abundance of their genomes detected in these tissues (relative to HAd5) suggests sequestration of these serotypes in tissues not tested in this study. We recently found that in addition to spleen and liver, significant levels of vectorized HAd4 genomes accumulated in the bone marrow 24 h after i.v. injection. 30 These results indirectly suggest that while HAd4 and group A members HAd31 and HAd12 are able to bind to CAR in vitro, their ability to target CARrich tissues (such as the murine liver) in vivo cannot be assumed. 8 To further evaluate the innate response to alternative serotype Ads, we characterized both the expression of innate immune response genes as well as the plasma cyto/chemokine profiles elicited shortly after i.v. injection of each alternative serotype wild-type virus. In our previous publications, we have shown that at 6 h.p.i., HAd5 induces a variety of immune response pathways in the liver following i.v. injection, and that the HAd5-induced transcriptome dysregulation profile was Innate immune responses to alternative Ad serotypes DM Appledorn et al dependent on functional complement and TLR systems. 9, 10 In this study, we found that HAd3, SAd23 and HAd41 induced many of these genes to a greater degree than did HAd5 despite the presence of three-to fivefold more virions in a group of HAd5 injections. These findings not only strengthen our conclusions that alternative Ad serotypes may induce more toxic immune responses than HAd5, but that the method of viral quantification must be carefully evaluated on a per serotype basis to assure proper dosages. In contrast to our previous studies, we did not observe dramatic differences in the expression of these same genes in complement-deficient mice, at least at the viral doses utilized. In fact, in both C3-and FB-deficient mice, we observed significantly higher levels of expression of several genes in the liver following HAd3 injection, and in the spleens of mice injected with SAd23. These results may suggest that complement opsonization may influence subsequent tissue-specific transcriptome responses to Ads in a serotype-specific fashion.
In lung, we found that in accord with biodistribution analyses, HAd3 induced both positive and negative regulators of immune responses to a greater extent than did HAd5, SAd23 or HAd41. Surprisingly, we also Figure 7 HAd3-and SAd23-induced thrombocytopenia, biodistribution and liver toxicity in complement-deficient mice. (a) Blood was collected from uninjected (N), mock-, HAd3-or SAd23-injected C3-or FB-deficient animals at 24 h.p.i. Platelets were counted as described in Materials and methods. n ¼ 10 for C57BL/6 mock, n ¼ 6 and n ¼ 5 or C57BL/6 mice injected with either HAd3 or SAd23, respectively. For C3-injected animals, n ¼ 3 for mock, n ¼ 3 for HAd3 and n ¼ 4 for SAd23. For FB data, n ¼ 5 for mock, n ¼ 4 for Ad3 and n ¼ 7 for SAd23. (b) At 6 and 24 h.p.i., DNA was extracted from the indicated mouse tissue and subjected to qPCR for quantification of HAd genomes per cell. For SAd23, n ¼ 3 for both tissues at 6 h.p.i. and n ¼ 2 for both tissues at 24 h.p.i. n ¼ 4 for both C3-and FB-deficient animals at both 6 and 24 h.p.i. HAd3-injected animals, n ¼ 3 and 2 for C57BL/6 mice at 6 and 24 h.p.i., respectively, n ¼ 3 for C3-and FB-injected animals in both tissues at both 6 and 24 h.p.i. (c) ALT activity was determined at 24 h.p.i. from C57BL/6, C3-and FB-deficient mouse plasma following injection with phosphate-buffered saline (mock), HAd3 or SAd23. For mock-injected animals, n ¼ 3 for C57BL/6 and C3-deficient animals, n ¼ 5 for FBdeficient mice. For HAd3-injected mice, n ¼ 4 for C57BL/6 mice and FB-deficient mice and n ¼ 3 for C3-deficient mice. For SAd23, n ¼ 5 for C57BL/6 mice and n ¼ 4 for both C3-and FB-deficient animals. An '*' represents a statistically significant difference (Po0.05), and '**'(Po0.01). Data is reported as mean ± s.d. Ad, adenovirus; ALT, alanine aminotransferase.
Innate immune responses to alternative Ad serotypes DM Appledorn et al observed a significant induction of most of these genes in lung tissue collected from mice injected with HAd31 and HAd37, serotypes that were not as tropic for lung tissue as was HAd3. These results suggest that lung responses to Ad exposure may, in part, be due to serotype-specific interactions with other innate immune response systems, or cell types not within the lung per se.
Furthermore, we found that many of the gene inductions following HAd3 injection were primarily dependent on the presence of a functional FB protein, and not as dependent on the presence of a functional C3 protein, as we have previously noted in studies of HAd5-based vectors in Ad naïve mice. 10 This suggests a primary role for FB (and the alternative complement pathway) in these aspects of Ad sensing in general, a role that may be more important than C3. This is not unprecedented, as it has been shown that several innate immune responses may be solely dependent on FB functionality. For example, FB can have direct actions on several cellular targets, even in the absence of C3, that is, enhancing microbicidal activity and spreading of monocytes and macrophages, decreasing B cell proliferation and as a plasminogen activator during fibrinolysis. [61] [62] [63] [64] [65] It is also interesting to note that the greatest level of IRF7 induction was found within the lung of animals injected with all serotypes tested. This latter result may indicate that Ad induction of lung IRF genes may be induced secondary to the influx of systemic cytokines, or that in lung tissue, interactions with even small amounts of Ads are sufficient to induce a potent interferon-related response.
Although there was a modest increase, we were also surprised to find that injection of these viruses did not dramatically affect the expression of many immune response genes in the spleen. On further analysis, we found that in parallel to studies in human tissues, the endogenous expression of these genes in mock-injected animals was significantly higher in the spleen than in the liver, and in most cases was also significantly higher compared with lung tissue. 66 It is possible that because these genes are already expressed at high levels in this tissue, their induction by systemically injected Ads is either less significant, or limited to only a low percentage of spleen cells, and thus not detectable by the methods utilized in this study.
Residing in liver sinusoids, Kupffer cells provide the first line of defense following injection of Ad and may be a main source of systemic cytokines released shortly after viral injection. [67] [68] [69] Kupffer cell death is observed at 4 h.p.i. of first-generation HAd5 vectors, and complete elimination is observed by 24 h.p.i. 44 In this study, we observed complete depletion of Kupffer cells following injection with two different doses of HAd5, as well as HAd3, and SAd23. In contrast, we saw a 60-70% reduction of Kupffer cells in the livers of mice injected with HAd31, HAd37 or HAd41. Intriguingly, Kupffer cell toxicity did not correlate with increased gene expression in liver tissue, thrombocytopenia, or plasma cyto/ chemokine levels. For example, HAd5 eliminated most Kupffer cells, and yet did not elicit significant thrombocytopenia and had significantly decreased cyto/chemokine or gene transcriptome responses compared with HAd3 or SAd23. These results suggest that serotypespecific Ad interactions with other cell types, such as endothelial cells or platelets, may also be responsible for these responses. 70 We, and others, have shown that plasma induction of the chemokine KC occurs within 1 h following i.v. injection of first-generation Ad vectors. [9] [10] [11] Interestingly, KC was induced by HAd5 and HAd3, but not by Ads representing groups A, D and F or group E-like SAd23. The mechanism behind differential induction of KC is currently unclear, but our results suggest that this induction appears to be receptor independent. More likely, rapid interactions with blood (that is, complement proteins) and/or cellular innate immune response elements (that is, tissue macrophages, endothelial cells) are key mediators of these differences, as the induction is within 1 h.p.i., too early for a response based purely on the nucleic acid differences inherent to the various virus serotypes. 71 Other chemotactic CC family cytokines induced by Ad include MCP-1 (CCL2), MIP-1b (CCL4) and RANTES (CCL5). At the doses tested in this study, we observed induction of MCP-1 by all serotypes tested except for HAd5 and MIP-1b by both HAd3 and SAd23. The latter appear to be the most immunogenic of the Ad serotypes tested, as HAd3 and SAd23 injections also precipitated acute clinical toxicities shortly after virus injection. These observations support recent data collected in our lab and a recent report that partially describes acute toxicities precipitated following i.v. injection of HAd3 and HAd4. 30, 60 Here, we also show that injections of HAd3 or SAd23 result in thrombocytopenia and ALT induction, and potentiated the highest plasma concentrations of IL-6, IL-1a, G-CSF, MCP-1 and MIP-1b. Because Ad-induced cytokine and chemokine responses are partially driven by the induction of type I IFNs, it is possible that some of the varied inflammatory responses observed in this study result from variable type I IFN production. 38 For example, chimpanzee-derived Ads have been shown to induce greater levels of type I IFNs than do HAd5 vectors both in vitro and in vivo. 72, 73 This may partially explain the increased immune response to SAd23 observed in this study. Importantly both HAd3 and SAd23 specifically activated the alternative complement pathway in human serum, and the induction of IL-1a, MCP-1 and MIP-1b, and IL-10 were in part complement dependent in our mouse model. Additionally, HAd41 and HAd37 induced plasma elevations of IL-6, IL-12, IFN-g, RANTES and MCP-1, but did not induce G-CSF. Interestingly, these two Ad serotypes were well tolerated following injection, whereas HAd37 induced mild thrombocytopenia, suggesting that HAd37 and HAd41 parallel responses induced by HAd5, but have reduced inherent Kupffer cell toxicity. These results suggest that HAd41-or HAd37-based vectors may be very useful as vaccine vectors. Conversely, injection of the group A member HAd31 only resulted in induction of the antiinflammatory cytokine IL-10, RANTES and MCP-1. For this reason, HAd31 might be considered a candidate for gene-therapy-based applications, although further investigation into its overall pattern of biodistribution is required.
The primary goal for proposing use of alternative serotype Ad vectors is the development of a repeated injection regimen that avoids the problem of pre-existing, anti-HAd5 immunity. 
Materials and methods
Adenovirus vector production and characterization
All Adenoviral serotypes used in this study were purchased from the American Type Culture Collection (ATCC)-catalog numbers: VR-1516 (Ad5), VR-847 (HAd3), VR-592 (SAd23), VR-1109 (HAd31), VR-929 (HAd37), VR-930 (HAd41). Each virus was grown to high titer by serial passaging in human 293 cells and purified as described previously. 76 The particle number titer of each virus preparation was quantified by SDSdisruption and OD 260 spectrophotometry essentially as described previously. 31 All purified viruses had similar OD 260/280 ratios indicating comparable DNA/protein content. To verify that particle number quantification was accurate across all serotypes, 10 10 purified virions of each serotype were separated by 8% SDS-polyacrylamide gel electrophoresis and subsequently stained with silver nitrate using a Silver stain kit for proteins (Sigma, St Louis, MO, USA). The amount of hexon protein was quantified for each serotype by scanning densitometry using ImageJ software, version 1.29 (developed at the U.S. National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). Results from this analysis indicated that the total viral particles injected of each serotype were within a twofold window, except for HAd5, where fivefold more hexon protein was observed compared with HAd37 based on normalization to particle number titers generated by SDS-disruption and OD 260 spectrophotometry (data not shown). For this reason, two doses of HAd5 were administered representing 7.5 Â 10 10 viral particles based on either OD 260 DNA quantification-based methods, HAd5(D), or doses equivalent to other alternative serotype viruses based on protein quantification, HAd5(P). Note that all statistical comparisons made against HAd5 were made using values obtained with HAd5(D), as this was the method of quantification used for all other serotypes tested.
Animal procedures
Adult C57BL/6 mice and B6.129S4-C3tmlCrr mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). FB-deficient mice, on the C57BL/6 background, were a generous gift from Dr Alex Szalai, University of Alabama. When required, mice were anesthetized with a nose cone containing isoflurane. 
Ad genome copy number per diploid genome
To assess the number of Ad genome copies per cell, tissues were snap-frozen in liquid nitrogen and then crushed to a fine powder using a mortar and pestle. DNA was extracted from frozen mouse tissue as described previously. 77 Copy numbers were assessed using real-time PCR-based quantification. PCR reactions were performed on an ABI 7900HT Fast Real-Time PCR System using the SYBR Green PCR Mastermix (Applied Biosystems, Foster City, CA, USA). Primers used to amplify unique regions of each Ad are found in Supplementary Table 1 . As an internal control for insuring adequate DNA amplification, cellular DNA was quantified using primers spanning a region of the murine glyceraldehyde-3-phosphate dehydrogenase sequence. All PCRs were subjected to the following procedure: 95.0 1C for 10 min, followed by 40 cycles of 95.0 1C for 15 s, followed by 60.0 1C for 1 min. Standard curves were run in duplicate and consisted of six half-log dilutions using total genomic DNA or DNA extracted from the purified viruses of each respective Ad serotype being tested. These standard curves were used to determine the number of viral genomes present per cell from each tissue sample. Melting curve analysis confirmed the quality and specificity of the PCR (data not shown).
ELISA cytokine and chemokine detection
To characterize Ad-induced systemic inflammatory responses, the plasma levels of an array of chemokines and cytokines were investigated using a multiplexed ELISA-based system, as described previously. 9 Blood was collected at 1, 6 and 24 h.p.i. using heparinized capillary tubes and EDTA-coated microvettes (Sarstedt, Nü mbrecht, Germany) and immediately centrifuged at 3400 rpm to isolate plasma. Plasma samples were analyzed using the Bio-Rad 100 Luminex Array reader and the Bio-Rad, BioPlex Murine Cytokine 23-plex kit according to the manufacturer's recommendations. Statistically significant differences between samples were determined using ANOVA with a Dunnet's post hoc test to determine a significant difference compared with mock-injected animals. Furthermore, an ANOVA with a Tukey's post hoc test was used at each time point to determine significant differences compared with wild type HAd5(D)-injected animals or to determine whether a significant difference existed between animals injected with a respective Ad serotype at a given time point. Bars represent means, while error bars indicate standard deviations.
Platelet enumeration
To assess Ad vector-induced thrombocytopenia, platelets were measured at the respective time points by using the Unopette (Fisher-Scientific) system as described previously. 9, 10 As per manufacturer's recommendations, RBCs were lysed and platelets were counted using a Neubauer hemocytometer. Statistically significant differences for platelet measurements were determined using ANOVA with Dunnet's post hoc test, as compared with platelet counts determined in mock-injected animals.
Innate immune responses to alternative Ad serotypes DM Appledorn et al Plasma ALT levels as a measure of liver toxicity Evidence of liver toxicity was quantified by measuring plasma ALT activity levels in plasma collected at 24 h.p.i. ALT activity was determined spectrophotometrically using Infinity-ALT from Thermoelectron Corp, according to the manufacturer's protocol (Louisville, CO, USA).
Quantitative reverse transcription-PCR analyses
To determine relative levels of a specific gene's RNA transcript, tissues were snap-frozen in liquid nitrogen and RNA was collected from E100 mg of frozen tissue using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) per the manufacturer's protocol. Following RNA isolation, reverse transcription was performed on 180 ng of total RNA using SuperScript II (Invitrogen) reverse transcriptase and random hexamers (Applied Biosystems) per manufacturer's protocol, excluding RNase-OUT. Reverse transcription reactions were diluted to a total volume of 60 and 2 ml was used as the template in the subsequent PCR reactions. Primers were designed using Primer Bank web-based software (http:// pga.mgh.harvard.edu/primerbank/) and are shown in Supplementary Table 1. qPCR was carried out on an ABI 7900HT Fast Real-Time PCR System using SYBR Green PCR Mastermix (Applied Biosystems) in a 15 ml reaction. All PCRs were subjected to the following procedure: 95.0 1C for 10 min, followed by 40 cycles of 95.0 1C for 15 s, followed by 60.0 1C for 1 min. The comparative C t method was used to determine relative gene expression using glyceraldehyde-3-phosphate dehydrogenase to standardize expression levels across all samples. For studies in complement-deficient mice, relative expression increases were calculated based on levels of a respective transcript quantified in mock-injected animals of the same genotype. In Table 1 , one-way ANOVA followed by a Dunnet's post hoc test was used to determine whether a statistical difference existed between each group and mock-injected mice (light gray boxes), while a Tukey's post hoc test was used to determine whether a statistical difference existed between each group versus HAd5(D)-injected animals (Dark gray; bold outlined boxes). In this analysis, n ¼ 3 for mock in liver, lung and spleen tissues. In liver, n ¼ 4, 3, 3, 3, 3, 3 and 3 for C57BL/6 mice injected with HAd5(P), HAd5(D) HAd3, SAd23, HAd31, HAd37 and HAd41, respectively. In lung, n ¼ 4, 6, 3, 3, 4, 3 and 3. In spleen, n ¼ 4, 3, 3, 3, 4, 4 and 3. In Table 2 , one-way ANOVA with Tukey's post hoc test was used to determine statistically significant differences. Gray boxes represent statistically higher levels of gene expression compared with the other two samples. Dark gray boxes indicate statistically higher levels of gene expression compared with light gray boxes, which are significantly higher than unshaded boxes. In this analysis, livers from mice injected with HAd3, n ¼ 3, 3, 3 for C57BL/6, C3-and FB-deficient mice, respectively. Similarly, n ¼ 3, 4 and 4 for mice injected with SAd23. In lung, n ¼ 3, 3 and 3 and n ¼ 3, 4 and 4 for mice in injected with HAd3 or SAd23, respectively. In Spleen, n ¼ 3, 3 and 3 and n ¼ 3, 4 and 3 for HAd3 or SAd23, respectively.
Kupffer cell staining
Liver blocks, preserved in OCT compound at À80 1C, were sliced into 8 mM sections using a Leica CM1850 cryostat, placed on glass slides and frozen at À80 1C for future use. Slides were thawed, fixed in 100% ethanol for 15 min, and washed in KPBS containing 0.2% gelatin and 0.05% tween-20. Sections were permeablized in 0.1% triton-X100 and blocked with KPBS containing 0.1% gelatin, 1% tween-20 and 5% BSA for 60 min at room temperature. To prevent nonspecific binding of the secondary antibody, 5% rabbit serum in wash buffer was added and incubated at room temperature for 30 min. Rat anti-mouse F4/80 antibody (Invitrogen) diluted to 5.2 mg ml À1 in wash buffer containing 2% rabbit serum was added to the sections and incubated overnight at 4 1C. Sections were washed and incubated at room temperature for 45 min with rabbit anti-rat Alexafluor488 (Invitrogen) secondary antibody diluted 1:25 000 in wash buffer containing 2% rabbit serum. Sections were then washed, stained with 4,6-diamidino-2-phenylindole (Invitrogen) for 5 min at room temperature and mounted using VECTASHIELD (Vector Laboratories, Burlingame, CA, USA). Images were obtained using a Leica DMLB microscope and captured using SPOT software version 3.5.9. Both 4,6-diamidino-2-phenylindole and F4/80-stained images were transferred to Adobe Photoshop and converted to grayscale. The background threshold was set based on mock-injected livers and pixels were quantified. F4/80 fluorescence values were normalized to 4,6-diamidino-2-phenylindole fluorescence values to control for cell number differences. Values are reported as percent of Kupffer cells identically enumerated in mock-injected livers. Statistics were completed using one-way ANOVA followed by Dunnet's test to determine statistical differences compared with mock, whereas Tukey's post hoc test was used to determine statistical differences between individual samples.
Complement activation assays
Buffers and reagents. Veronal-buffered saline, pH 7.4 (VBS), Veronal-buffered saline containing 0.1% (W/V) gelatin, 0.15 mM CaCl 2 and 1 mM MgCl 2 (GVBS++). Dextrose (10%) six parts, GVBS four parts containing 0.15 mM CaCl 2 and 1 mM MgCl 2 (DGVBS++). GVBS containing 8 mM EGTA and 5 mM MgCl 2 (EGTA-GVBS++). GVBS containing 10 mM EDTA (EDTA-GVBS). All chemicals were purchased from Sigma Chemical Co. (St Louis, MO, USA).
Complement depleted sera and antibodies. C4-deficient guinea pig serum, sheep and rabbit blood were supplied by Duke Vivarium staff. Anti-sheep red cell antibody (rabbit hemolysin) was prepared as described previously. ) in 500 ml. EGTA-GVBS++ was added to each test tube to bring the total volume to 1 ml. Serum mixtures were incubated at 37 1C for 60 min with shaking. Two milliliter of EDTA-GVBS was added to stop the reaction. After centrifugation, the optical density of the supernatant was measured at 412 nm.
C4 hemolytic activity. Erythrocytes (1.5 Â 10 8 ) in 200 ml DGVBS++ were incubated with 200 ml of a 1:90 dilution of C4-deficient guinea pig serum in the same buffer. To this mixture, 200 ml of diluted human serum (from 1:1000 to 625 000), with or without preincubation with 1 Â 10 12 viral particles per ml in GVBS++, was added. The mixture was then incubated at 37 1C for 3 h. A 2 ml volume of EDTA-GVBS was added to stop the reaction. After centrifugation, the optical density of the supernatant was measured at 412 nm. Aggregated human IgG (10 mg ml
À1
) was used to activate classical complement as control. C4 was consumed in the assay. Control samples were set at 100% activity and compared to the activity elicited by the respective serotype used in the assay. The data in this report are representative of the results obtained after three biological replicates were completed.
